United-Guardian FY2025 Sales Drop 13% to $10.55M, Pharma Sales Up 15%
United-Guardian's FY2025 net sales fell 13% to $10.55 million, dragging net income down 35% to $2.11 million, or $0.46 per share. Pharmaceutical sales rose 15% and medical lubricant sales climbed 4% as new formulary approvals and contract manufacturing demand offset cosmetic ingredient headwinds.
1. FY2025 Financial Results
United-Guardian reported net sales of $10.55 million for fiscal 2025, down 13% from $12.18 million in 2024, while net income declined 35% to $2.11 million, or $0.46 per share, compared with $3.25 million, or $0.71 per share, in the prior year.
2. Segment Performance
Sales of cosmetic ingredients fell sharply due to excess inventory at the largest distributor and reduced global demand, particularly in China, while pharmaceutical sales increased 15% driven by higher wholesaler orders and lower Medicare rebates, and medical lubricant sales rose 4% from increased contract manufacturing demand in China.
3. Strategic Initiatives
The company is collaborating with its Chinese distributor to recapture market share through competitive pricing and product differentiation, launching a new Renacidin marketing strategy that secured two major pharmacy benefit manager formulary approvals, and exploring new markets to offset tariff and competition pressures.